JBIO at a glance
Jade Biosciences, Inc. (JBIO, SEC CIK 1798749) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 30, 2026 and Form 4 insider filings as recently as June 26, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Jade Biosciences, Inc. (JBIO) shares worth $558.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $558.5M · +6 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes stated in provided Risk Factors section relative to the 2025 10-K
- Liquidity risk: $461.2 million in cash, cash equivalents, and investments expected to fund operations for at least twelve months
- Clinical-development risk: $86.1 million research and development expense through June 30, 2026
- Operating-loss risk: $96.1 million net loss and $67.7 million operating cash outflow in six months
- Investment risk: $353.955 million marketable securities with $568 thousand unrealized losses
AI summary of the JBIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- JADE301 showed selective IFN-ß neutralization, with 11.3 pM binding affinity and 13 pM pSTAT inhibition
- Dermal fibroblast MX-1 inhibition reached 11 pM, approximately 8-fold more potent than dazukibart
Item 2.02: Results of Operations and Financial Condition
- Quarterly results covered period ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
Item EX-99.1: Item EX-99.1
- Positive interim JADE101 data: approximately 70% mean IgA reduction after one 700 mg dose, supporting potential every-12-week maintenance dosing
- JADE101 Phase 2 underway with interim data expected in 2027; Phase 3 planned for first half of 2027 pending FDA feedback
Item 1.01: Entry into a Material Definitive Agreement
- Exclusive worldwide, sublicensable JADE301 license expands Jade’s pipeline across all therapeutic areas
- Up to $22.0M in development and regulatory milestones, including $2.5M upon first Phase 1 patient dosing
AI summaries of JBIO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for JBIO
Don't miss the next JBIO filing
- Alerts as it files. A push when JBIO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut JBIO, by share count.
- Ask anything. An AI agent that reads every JBIO filing and answers with sources.
JBIO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Eisner Mark | A | Jun 25, 2026 | 47,675 | - |
| Fairmount Funds Management LLC | A | Jun 9, 2026 | 34,843 | - |
| Lavelle Erin | A | Jun 9, 2026 | 34,843 | - |
| Klein Lawrence Otto | A | Jun 9, 2026 | 34,843 | - |
| CAIN CHRISTOPHER W. | A | Jun 9, 2026 | 34,843 | - |
| DOBMEIER ERIC | A | Jun 9, 2026 | 34,843 | - |
| Dahms Bradford D. | A | Feb 12, 2026 | 226,875 | - |
| King Andrew James | A | Feb 12, 2026 | 41,250 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$81.4M | -$74.6M | -$113.5M |
| Net Income | -$75.5M | -$69.6M | -$127.4M |
| Balance Sheet | |||
| Total Assets | $127.4M | $80.3M | $349.8M |
| Equity | $109.5M | $76.4M | $332.5M |
| ROE | -69.0% | -91.1% | -38.3% |
| Per Share | |||
| EPS | $-2.87 | $-2.44 | $-3.19 |
| Cash Flow | |||
| Operating CF | -$56.8M | -$71.2M | -$94.7M |
| CapEx | $142K | - | $196K |
Source: XBRL data in Jade Biosciences, Inc. (JBIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate JBIO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $558.5M |
| Q1 2026 | 21 | $185.1M |
| Q4 2025 | 20 | $212.1M |
| Q3 2025 | 16 | $85.8M |
| Q2 2025 | 13 | $91.0M |
- FMR LLC (Fidelity)+2.04M (+29%)
- State Street Corp+1.68M (+256%)
- JPMorgan Chase & Co+1.46M (+9199%)
- Citadel Advisors LLC+792.2K (+577%)
- Goldman Sachs Group+582.2K (+380%)
- Renaissance Technologies LLC−61.4K (-46%)
- Invesco Ltd−11.4K (-39%)
- BNY Mellon−4.6K (-5%)
- PNC Financial Services−2 (-2%)
- Franklin Resources+2.79M
- Blackstone Group+435.3K
- Ameriprise Financial+107.1K
- Raymond James Financial+78.7K
- D.E. Shaw & Co+51.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 97 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
JBIO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 17, 2026 | - | - | |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Apr 22, 2026 | - | Analysis | - |
| 8-K | Apr 2, 2026 | - | Analysis | - |
| 10-K | Mar 6, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 6, 2026 | - | Analysis | - |
| SC 13G | Feb 17, 2026 | - | - | |
| SC 13G | Feb 17, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
JBIO SEC filings: frequently asked questions
Which institutions hold JBIO stock?
As of June 30, 2026, the largest Jade Biosciences, Inc. (JBIO) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($202.8 million), BlackRock ($62.2 million), Franklin Resources ($62.0 million), State Street Corp ($51.9 million), Vanguard Capital Management LLC ($49.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did JBIO report in its latest 8-K?
Jade Biosciences, Inc. (JBIO) filed an 8-K on September 30, 2026 reporting Item 8.01 (Other Events). JADE301 showed selective IFN-ß neutralization, with 11.3 pM binding affinity and 13 pM pSTAT inhibition.
What are the latest JBIO SEC filings?
Jade Biosciences, Inc. (JBIO) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 30, 2026 and a Form 4 insider filing on June 26, 2026.
What is JBIO's SEC CIK number?
Jade Biosciences, Inc. (JBIO)'s SEC Central Index Key (CIK) is 1798749. EDGAR lists every JBIO filing under that number.
Ask anything about JBIO
The research agent reads JBIO's filings, financials, insider trades and 13F holders, then answers with sources.